Although biologics such as TNF antagonists revolutionized the treatments of chronic inflammatory diseases including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA), a large portion of patients do not respond or develop resistance to these drugs (1), necessitating alternative medicines to treat them. The gene discussed is TNF; the disease is inflammatory bowel disease.